Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Journal Information
Full Title: Ther Adv Respir Dis
Abbreviation: Ther Adv Respir Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest statement: Joline Lim has no conflict of interest. Ross Soo has received honoraria from Astra-Zeneca, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, and Roche."
"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ross Soo is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025